GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Cyclically Adjusted PB Ratio

Sophiris Bio (Sophiris Bio) Cyclically Adjusted PB Ratio : (As of May. 02, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sophiris Bio Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sophiris Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio Cyclically Adjusted PB Ratio Chart

Sophiris Bio Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sophiris Bio Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sophiris Bio's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sophiris Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophiris Bio's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's Cyclically Adjusted PB Ratio falls into.



Sophiris Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sophiris Bio's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Sophiris Bio's adjusted Book Value per Share data for the three months ended in Sep. 2019 was:

Adj_Book=Book Value per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-0.082/108.3294*108.3294
=-0.082

Current CPI (Sep. 2019) = 108.3294.

Sophiris Bio Quarterly Data

Book Value per Share CPI Adj_Book
200912 0.924 91.111 1.099
201003 2.580 91.821 3.044
201006 3.096 91.962 3.647
201009 2.430 92.162 2.856
201012 4.842 92.474 5.672
201103 4.157 94.283 4.776
201106 2.955 95.235 3.361
201109 1.764 95.727 1.996
201112 2.525 95.213 2.873
201203 3.504 96.783 3.922
201206 1.666 96.819 1.864
201209 -0.006 97.633 -0.007
201212 -1.621 96.871 -1.813
201303 -1.550 98.209 -1.710
201306 -2.239 98.518 -2.462
201309 2.816 98.790 3.088
201312 2.494 98.326 2.748
201403 2.061 99.695 2.240
201406 1.614 100.560 1.739
201409 1.158 100.428 1.249
201412 0.872 99.070 0.954
201503 0.629 99.621 0.684
201506 0.420 100.684 0.452
201509 0.214 100.392 0.231
201512 0.111 99.792 0.120
201603 -0.011 100.470 -0.012
201606 0.034 101.688 0.036
201609 0.484 101.861 0.515
201612 0.476 101.863 0.506
201703 0.403 102.862 0.424
201706 0.439 103.349 0.460
201709 0.373 104.136 0.388
201712 0.254 104.011 0.265
201803 0.151 105.290 0.155
201806 -0.045 106.317 -0.046
201809 -0.132 106.507 -0.134
201812 0.057 105.998 0.058
201903 -0.013 107.251 -0.013
201906 -0.079 108.070 -0.079
201909 -0.082 108.329 -0.082

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sophiris Bio  (OTCPK:SPHS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sophiris Bio Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophiris Bio (Sophiris Bio) Business Description

Traded in Other Exchanges
N/A
Address
1258 Prospect Street, La Jolla, CA, USA, 92037
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.
Executives
Randall E Woods director, officer: President & Chief Exec Officer C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell director
Gerald T Proehl director
John Geltosky director 685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn director PO BOX 676367, RANCHO SANTA FE CA 92067